

The Characterization of Fusidic Acid-selected *fusA* Mutants of *faiR* Deletion Mutants of *Staphylococcus aureus*

Authors: Daniel Henthorn, Nathaniel Torres, John Gustafson*
Department of Biochemistry and Molecular Biology, Oklahoma State University

Abstract

This project analyzed a gene (*faiR*) in *Staphylococcus aureus*, which is thought to be a regulator within an efflux pump operon that had been previously found in the laboratory. The characterization focused primarily on fusidic acid resistance expression. Initially fusidic acid-resistant mutants were selected from both a parent strain and a mutant missing *faiR* culture that had the gene of interest inactivated. The data suggests that *faiR* and perhaps the *faiRAB* operon, has no impact on fusidic acid resistance expression. Furthermore, screening for the effects of *faiR* deletion on susceptibility to other antibiotics demonstrated that this gene and possibly the *faiRAB* operon do not play a role in intrinsic antimicrobial resistance in *S. aureus*.

Keywords: *Staphylococcus aureus*, fusidic acid, efflux pump

Introduction

Staphylococcus aureus is a Gram-positive human opportunistic pathogen that harbors numerous virulence factors and can readily acquire horizontally-transmitted genes that allows the organism to impede the effects of antibiotics (Lowy 2003). One of the more-well known examples of antibiotic-resistant *S. aureus* is methicillin-resistant *S. aureus* (MRSA) (Lowy 2003) and in 2011, MRSA led to 80,000 infections and to 11,000 deaths within the United States (Center for Disease Control 2003).

Fusidic acid is a steroid antibiotic that was clinically introduced in the 1960s to treat *S. aureus* infections that is currently used widely throughout Europe and soon to be licensed for use in the United States (Moellering et al. 2011), (Howden and Grayson 2006). Fusidic acid inhibits protein synthesis by binding to the ternary complex of elongation factor G (EF-G), guanosine diphosphate (GDP), and the ribosome (Tanaka et al. 1968), (Cundliffe 1972). Therefore, fusidic acid causes the ribosome to stall on the mRNA strand and inhibits translation (Collignon and Turnidge 1999).

Resistance to fusidic acid by *S. aureus* is mediated by two distinct mechanisms. The first is through mutations that occur within the gene that codes for EF-G, *fusA*, and the second is due to the acquisition of *fusB* or *fusB* homologues, which have been given names such as *fusC* and *fusD* (Nagaev et al. 2001), (O'Brien et al. 2002), (O'Neill et al. 2007). These mutations and acquired genes are thought to lead to a reduction in the binding affinity between EF-G and fusidic acid and as a result negate the effects of the antibiotic (Nagaev et al. 2001). *fusA* mutants of *S. aureus* can be easily isolated in the laboratory from *S. aureus* populations following fusidic acid selection, as seen in this experiment.

Our laboratory previously discovered two genes that were induced by growth in the presence of fusidic acid (Delgado et al. 2008) and are here named as fusidic acid induced A and B (*faiA* and *faiB*). Both genes are thought to code for a bipartite multidrug efflux pump. Efflux pumps are important to bacterial survival in the presence of actively efflux antibiotics as the

outside of the cell (Van Bambeke et al. 2000). *faiA* encodes a single membrane spanning protein of 215 amino acid bases that is a member of the resistance-nodulation-division (RND) family of transport proteins (Lomovskaya and Lewis 1992). *faiB* encodes a protein that is a homologue to the *S. aureus* major facilitator superfamily (MFS) proteins *LmrS* and *MdeA*, which are thought to efflux fusidic acid (Floyd et al. 2010), (Huang et al. 2004). Upstream of *faiA* lies the divergently encoded *tetR* homologue, *faiR*, that we hypothesize that *FaiR* controls the transcription of *faiAB*.

In order to have adaptable survival to an unstable environment with variables constantly changing and shifting, bacteria have adaptive responses triggered by regulatory proteins that, in response to environmental signals, alter transcription (Ramos et al. 2005). One large family of these regulators is TetR, known to be a regulator of the *tet* genes, which confer resistance to tetracycline (Ramos et al. 2005). One known TetR homologue in *S. aureus* is *QacR*, which is responsible for the regulation of the multidrug efflux pump gene, *qacA* (Grkovic et al. 1998). Another known TetR in *Staphylococcus aureus*, which is associated with regulation of the *ica* locus, which is involved with the production of biofilm, is *IcaR* (Jefferson et al. 2003). Another *S. aureus* TetR homologue, *FaiR* is hypothesized to be the regulator of its adjacent genes *faiAB*, which codes for a putative antimicrobial efflux pump.

In this project we will determine if the deletion of *faiR* will affect the level of fusidic acid resistance expressed by a fusidic acid-selected *fusA* mutant of strain *JE2ΔfaiR* previously constructed in our laboratory. We hypothesized that if *faiR* acts as a negative regulator of *faiAB* expression, and *faiAB* supports fusidic acid resistance,

that the *JE2ΔfaiR-fusA* mutants would express a higher level of fusidic acid resistance, compared to *JE2fusA* mutants.

Methods

S. aureus strain *JE2* (Fey et al. 2013) (USA300) is a community-associated MRSA strain, cured of all plasmids and was utilized for this study. We first selected for *JE2* and *JE2ΔfaiR* fusidic acid-resistant *fusA* mutants. To do so we started by making 2 mL overnight cultures of both strains. We then prepared Muller Hinton agar (MHA) plates which contained 2 μg/ml fusidic acid and inoculated these plates with 100 μL of undiluted overnight culture and incubated these plates overnight at 37°C. We then picked 3 isolated colonies for each strain, *JE2* and *JE2ΔfaiR*. These colonies chosen were then passaged twice on drug free MHA and incubated overnight at 37°C. We then used minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) techniques to determine the levels of resistance/susceptibility to fusidic acid expressed by *JE2* and *JE2ΔfaiR*, and the fusidic acid-selected *JE2fusA* and *JE2ΔfaiR-fusA* mutants. To do this we first created overnight cultures of each strain. We then diluted *JE2*, *JE2ΔfaiR*, and the fusidic acid-selected *JE2fusA* and *JE2ΔfaiR-fusA* mutants to an OD_{580nm} of 0.01. These diluted cultures were then put in test tubes with concentrations of fusidic acid from 0 μg/mL -1024 mg/ml in successive two-fold changes in concentration. The test tubes were then incubated statically overnight at 37°C. On the following day the MICs were determined and the MIC tube and tubes containing higher fusidic acid concentrations were plated onto drug free MHA and grown overnight at 37°C. The MBC was the concentration of fusidic acid where no growth was observed on the MHA plate following overnight growth

We then used Kirby Bauer methods to test for any possible changes in susceptibility/resistance to antibiotics, including fusidic acid. To do this, 2 mL MHB overnight cultures of JE2, JE2Δ*faiR*, and the fusidic acid-selected JE2*fusA*, and JE2Δ*faiR*-*fusA* mutants were prepared. These cultures were then diluted to an OD_{580nm} of 0.01. The diluted cultures were then plated onto large petri dish plates of MHA. Arrangements of antimicrobial assay disks were placed evenly and the plates were then incubated overnight at 37°C and the zones of growth inhibition were determined.

Table 1 - This table shows both the MIC and MBC results for resistance/susceptibility to fusidic acid.

Strain	MIC	MBC
JE2	2 µg/mL	8 µg/mL
JE2-FA-R-1	128 µg/mL	1024 µg/mL
JE2-FA-R-2	128 µg/mL	1024 µg/mL
JE2-FA-R-3	128 µg/mL	1024 µg/mL
JE2Δ <i>faiR</i>	2 µg/mL	8 µg/mL
JE2Δ <i>faiR</i> -FA-R-1	128 µg/mL	1024 µg/mL
JE2Δ <i>faiR</i> -FA-R-2	128 µg/mL	1024 µg/mL
JE2Δ <i>faiR</i> -FA-R-3	128 µg/mL	1024 µg/mL

Table 2 – This table shows the Kirby Bauer results.

Strain	SPT	LEV	TGC	RD	CAZ	FD	VA	TE	C
JE2	I	R	S	S	R	S	S	S	S
JE2-FA-R-1	I	R	S	S	R	R	S	S	S
JE2-FA-R-2	I	R	S	S	R	R	S	S	S
JE2-FA-R-3	I	R	S	S	R	R	S	S	S
JE2Δ <i>faiR</i>	I	R	S	S	R	S	S	S	S
JE2Δ <i>faiR</i> -FA-R-1	I	R	S	S	R	R	S	S	S
JE2Δ <i>faiR</i> -FA-R-2	I	R	S	S	R	R	S	S	S
JE2Δ <i>faiR</i> -FA-R-3	I	R	S	S	R	R	S	S	S

Results

Within this experiment, fusidic acid-resistant mutants of JE2 and JE2Δ*faiR* were successfully isolated with 2 µg/mL fusidic acid selection process. This can be confirmed using the MIC and MBC data, which showed that each of the fusidic acid selected strains had an MIC of 128 µg/mL and an MBC that grew over the highest fusidic acid concentration, which was 1024 µg/mL (Table 1).

The MIC and MBC data demonstrates that *faiR* deletion does not have a dramatic effect on the level of fusidic acid resistance expressed by JE2 and JE2Δ*faiR* and their fusidic acid-selected *fusA* mutants. There were also no significant change differences amongst the strains investigated in the zones of inhibition observed in the Kirby Bauer data (Table 2).

Discussion

S. aureus fusidic acid resistance has been well described in the literature. Since JE2 and JE2Δ*faiR* are derived from a strain that has been cured of all plasmids, the fusidic acid-resistant mutants of these strains are most likely a result of *fusA* mutations (Nagaev et al. 2001), (Chopra 1976) and not *fusB* acquisition (O'Brien et al. 2002). This is important because it can give possible insight as to the properties of the *faiRAB* operon not having an impact on the fusidic acid resistance. Clearly, from both the MIC and the MBC data given, the deletion of *faiR* does not have an impact on fusidic acid resistance levels or susceptibility to the antibiotics represented in the Kirby Bauer data. These results can lead to understanding more about the operon. It is possible as well that *faiR* does not regulate *faiAB*. Overall though, we would conclude that that *FaiA* and *FaiB* do not represent an antimicrobial efflux pump.



Nonetheless, because *faiAB* is induced by fusidic acid (Delgado et al. 2008) and because fusidic acid is a steroid antibiotic, it is likely that the inducer for the operon in nature is a steroid. It also remains possible the *FaiR* binds steroids. The conclusion of this work suggests that *faiR* and possibly *faiAB* (if *faiR* controls this locus) play no role in the intrinsic antimicrobial resistance mechanism in *S. aureus*.

Acknowledgements

This research was supported by a scholarship granted to freshman researchers at Oklahoma State University of Stillwater, Oklahoma by the Howard Hughes Medical Institute.

Literature Cited

- Center for Disease Control. 2003 Antibiotic Resistance Threats in the United States. <http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf>
- Chopra, I. 1976. Mechanisms of resistance to fusidic acid in *Staphylococcus aureus*. *J Gen Microbiol* 96 (2):229-238
- Collignon, P., and J. Turnidge. 1999. Fusidic acid in vitro activity. *Int J Antimicrob Agents* 12 Suppl 2:S45-58
- Cundliffe, E. 1972. The mode of action of fusidic acid. *Biochem Biophys Res Commun* 46 (5):1794-1801
- Delgado A., S. Zaman, A. Muthaiyan, V. Nagarajan, M.O. Elasri, B.J. Wilkinson, J.E Gustafson. 2008. The fusidic acid stimulon of *Staphylococcus aureus*. *J Antimicrob Chemother* 62 (6):1207-1214. doi:10.1093/jac/dkn363
- Fey, P.D., J.L. Endres, V.K. Yajjala, T.K. Widhelm, R.J. Boissy, J.L. Bose, K.W. Bayles. 2013. A genetic resource for rapid and comprehensive phenotype screening of nonessential *Staphylococcus aureus* genes. *MBio* 4 (1):e00537-00512. doi:10.1128/mBio.00537-12
- Floyd, J.L., K.P. Smith, S.H. Kumar, J.T. Floyd, M.F. Varela. 2010. *LmrS* is a multidrug efflux pump of the major facilitator superfamily from *Staphylococcus aureus*. *Antimicrob Agents Chemother* 54 (12):5406-5412. doi:10.1128/AAC.00580-10
- Grkovic, S., M.H. Brown, N.J. Roberts, I.T. Paulsen, and R.A. Skurray. 1998 *QacR* is a repressor protein that regulates expression of the *Staphylococcus aureus* multidrug efflux pump *QacA*. *J Biol Chem* 273 (29):18665-18673
- Howden, B.P., and M.L. Grayson. 2006. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in *Staphylococcus aureus*. *Clin Infect Dis* 42 (3):394-400. doi:10.1086/499365
- Huang, J., P.W. O'Toole, W. Shen, H. Amrine-Madsen, X. Jiang, N. Lobo, L.M. Palmer, L. Voelker, F. Fan, M.N. Gwynn, and D. McDevitt. 2004. Novel chromosomally encoded multidrug efflux transporter *MdeA* in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 48 (3):909-917
- Jefferson, K.K., S.E. Cramton, F. Gotz, and G.B. Pier. 2003. Identification of a 5-nucleotide sequence that controls expression of the *ica* locus in *Staphylococcus aureus* and characterization of the DNA-binding properties of *IcaR*. *Mol Microbiol* 48 (4):889-899
- Lomovskaya, O., and K. Lewis. 1992. *Emr*, an *Escherichia coli* locus for multidrug resistance. *Proc Natl Acad Sci U S A* 89 (19):8938-8942
- Lowy, F.D. 2003. Antimicrobial resistance: the example of *Staphylococcus aureus*. *J Clin Invest* 111 (9):1265-1273. doi:10.1172/JCI18535
- Moellering, R.C., Jr., G.R. Corey, and M.L. Grayson. 2011. Introduction: fusidic acid enters the United States. *Clin Infect Dis* 52 Suppl 7:S467-468. doi:10.1093/cid/cir171
- Nagaev, I., J. Bjorkman, D.I. Andersson, and D. Hughes. 2001. Biological cost and compensatory evolution in fusidic acid-resistant *Staphylococcus aureus*. *Mol Microbiol* 40 (2):433-439
- O'Brien, F.G., C. Price, W.B. Grubb, J.E Gustafson. 2002. Genetic characterization of the fusidic acid and cadmium resistance determinants of *Staphylococcus aureus* plasmid *pUB101*. *J Antimicrob Chemother* 50 (3):313-321
- O'Neill, A.J., F. McLaws, G. Kahlmeter, A.S. Henriksen, and I. Chopra. 2007. Genetic basis of resistance to fusidic acid in staphylococci. *Antimicrob Agents Chemother* 51 (5):1737-1740. doi:10.1128/AAC.01542-06

- 
- 
- Ramos, J.L., M. Martinez-Bueno, A.J. Molina-Henares, W. Teran, K. Watanabe, X. Zhang, M.T. Gallegos, R. Brennan, and R. Tobes. 2005. The TetR family of transcriptional repressors. *Microbiol Mol Biol Rev* 69 (2):326-356. doi:10.1128/MMBR.69.2.326-356.2005
- Tanaka, N., T. Kinoshita, and H. Masukawa. 1968. Mechanism of protein synthesis inhibition by fusidic acid and related antibiotics. *Biochem Biophys Res Commun* 30 (3):278-283
- Van Bambeke, F., E. Balzi, and P.M. Tulkens. 2000. Antibiotic efflux pumps. *Biochemical pharmacology* 60 (4):457-470